CTAG1B and melanoma: For instance, vaccination of melanoma patients with recombinant full-length NY-ESO-1 alone or in combination with the ISCOMATRIX adjuvant resulted in a strong induction of NY-ESO-1 specific antibodies, as well as an increase in specific CD4+ and CD8+ T cells (94).